Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05372484 · ClinicalTrials.gov registry record · NA

Rice Technologies for Cervical Cancer Screening and Diagnosis

A NA study of Cervical Cancer, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
678
Enrollment target
4
Study locations

NCT05372484 is a NA study of Cervical Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 678 participants, above the 566-participant average among 144 other Cervical Cancer trials with a reported enrollment target (20% higher). The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05372484, a NA study of Cervical Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
678 participants
Enrollment target
4
Study locations

Study Summary

The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.

Conditions Studied

Interventions

  • DEVICE Multimodal optical imaging

Study Locations (4)

Other

  • José Macamo General Hospital and Health Center - Maputo
  • Maputo Central Hospital - Maputo
  • Mavalane Hospital and Health Center - Maputo

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 678 participants
Start Date 2021-03-24
Est. Completion 2028-03-30
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT05372484

The ClinicalTrials.gov registry entry for NCT05372484 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 678 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 566-participant average among 144 other Cervical Cancer trials with a reported enrollment target (20% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which Multimodal optical imaging is the first listed.

NCT05372484 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.

Frequently Asked Questions

What is clinical trial NCT05372484 about?

NCT05372484 is a clinical study titled "Rice Technologies for Cervical Cancer Screening and Diagnosis". The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopatholo...

What is the current status of trial NCT05372484?

This trial is currently recruiting. It is a NA study. The enrollment target is 678 participants. The study started on 2021-03-24. Estimated completion is 2028-03-30.

What conditions does trial NCT05372484 study?

This clinical trial studies the following conditions: Cervical Cancer.

What interventions are being tested in trial NCT05372484?

The interventions under investigation include: Multimodal optical imaging (DEVICE).

Who is sponsoring clinical trial NCT05372484?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05372484 being conducted?

This trial has 4 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.